Emerging links between gut dysbiosis, aryl hydrocarbon receptor activation, and Parkinson’s disease
Abstract
Parkinson’s disease (PD), the second most common progressive neurodegenerative disorder, is classically defined as a motor disorder characterized by dopaminergic neuron loss in the substantia nigra and motor dysfunction. Increasing evidence, however, identifies PD as a multisystem disorder with early non-motor features, including sleep, psychiatric, and gastrointestinal disturbances, implicating the gut-brain axis. Tryptophan metabolism through serotonin, kynurenine, and indole pathways generates bioactive metabolites, many of which regulate the aryl hydrocarbon receptor (AhR). AhR is a ligand-activated transcription factor involved in xenobiotic metabolism through canonical signaling pathways; however, growing evidence supports its role in immune balance, glial responses, and barrier integrity. Altered AhR signaling may therefore connect gut dysbiosis and disrupted tryptophan metabolism to sustained, systemic and central inflammation in PD. This review examines gut dysbiosis, tryptophan metabolism, and AhR signaling as potential mechanisms underlying idiopathic PD and highlights their relevance to early diagnosis and disease-modifying therapies.
Related
- Gut epithelial aryl hydrocarbon receptor deficiency aggravates fungal dysbiosis-mediated neutrophilic allergic airway disease in mice
- Aryl Hydrocarbon Receptor (Ahr) Pathway Drives TBBPA Induced Cartilage Development Defects.
- The Gut–Kidney Axis in Chronic Kidney Disease: Microbial Dysbiosis, Host–Microbial Metabolism, and Emerging Therapeutic Strategies
- In vitro pharmacological profiling of ITE amide bioisosteric aryl hydrocarbon receptor agonist
- The Aryl Hydrocarbon Receptor spectrum in the human placenta: from development to environmental sensing and disease
BibTeX
@article{aziz2026emerging,
title = {{Emerging links between gut dysbiosis, aryl hydrocarbon receptor activation, and Parkinson’s disease}},
author = {Nastaran Farshchi Aziz and Sandhya Kortagere},
journal = {Communications Biology},
year = {2026},
month = oct,
doi = {10.1038/s42003-026-11156-1},
url = {https://www.nature.com/articles/s42003-026-11156-1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Emerging links between gut dysbiosis, aryl hydrocarbon receptor activation, and Parkinson’s disease
AU - Nastaran Farshchi Aziz
AU - Sandhya Kortagere
PY - 2026
DA - 2026/10/22
JO - Communications Biology
DO - 10.1038/s42003-026-11156-1
UR - https://www.nature.com/articles/s42003-026-11156-1
AB - Parkinson’s disease (PD), the second most common progressive neurodegenerative disorder, is classically defined as a motor disorder characterized by dopaminergic neuron loss in the substantia nigra and motor dysfunction. Increasing evidence, however, identifies PD as a multisystem disorder with early non-motor features, including sleep, psychiatric, and gastrointestinal disturbances, implicating the gut-brain axis. Tryptophan metabolism through serotonin, kynurenine, and indole pathways generates bioactive metabolites, many of which regulate the aryl hydrocarbon receptor (AhR). AhR is a ligand-activated transcription factor involved in xenobiotic metabolism through canonical signaling pathways; however, growing evidence supports its role in immune balance, glial responses, and barrier integrity. Altered AhR signaling may therefore connect gut dysbiosis and disrupted tryptophan metabolism to sustained, systemic and central inflammation in PD. This review examines gut dysbiosis, tryptophan metabolism, and AhR signaling as potential mechanisms underlying idiopathic PD and highlights their relevance to early diagnosis and disease-modifying therapies.
SN - 2399-3642
ER -